BioSET licenses Brookhaven Lab's synthetic growth factor technology

December 17, 2002

UPTON, NY -- BioSurface Engineering Technologies, Inc. (BioSET), of College Park, Maryland, has obtained an exclusive worldwide license to a novel growth factor technology developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory in collaboration with BioSET researchers. The Brookhaven-BioSET team made biologically active synthetic analogs of two growth factors, including basic fibroblast growth factor for use in wound healing and radiation protection, as well as other applications.

Fibroblast growth factor (FGF) refers to a family of proteins in the human body responsible for the proliferation, repair and survival of cells in many tissues, including the brain, vascular system, and muscle. Basic fibroblast growth factor is used clinically in Japan for the treatment of diabetic foot ulcers. It also has been evaluated in clinical trials in the U.S. for its ability to enhance neurological recovery after stroke and to minimize the effects of ischemia, or insufficient blood flow in the heart and circulatory system.

The new analogs developed at Brookhaven are proteins that are easier to produce than natural growth factors or growth factors derived by recombinant techniques. BioSET has taken an exclusive license to Brookhaven's bioactive analogs and improved techniques for making the analogs. Several of these bioactive analogs are currently in testing.

Thomas Roueché, BioSET's president, said, "Our team is committed to developing these new, bioactive coatings for the biomedical and biopharmaceutical industries. We are very encouraged by the performance of these totally synthetic growth factor analogs as compared to currently available recombinant growth factors, many of which are either already approved for use or are being evaluated in end-state clinical trials for the treatment of serious disease states. We believe synthetic analogs may provide a valuable alternative with improved safety, cost and efficacy."

"This technology is unique because these growth factor analogs are chemically synthesized," said Louis Peña, Brookhaven's principal researcher in the project. "This should result in significant cost savings, compared to current methods of producing growth factors, and it gives us a great deal of control in making useful modifications. Our studies show that the FGF analogs are active and biologically equivalent to natural FGF, and that they work in animal models of human disease. What makes some of this possible is that our analogs specifically adhere to BioSET's coatings."

Based on their preliminary research, the scientists believe the new growth factor technology will be important in developing local and regional therapies to treat wounds and other diseases, especially when combined with BioSET's heparin-based growth factor technology. BioSET's unique, modified heparin is a coating that allows local and regional delivery of proteins in their most bioactive form.

Paul Zamora, BioSET's chief scientific officer, said, "We view this as a platform technology to develop analogs to many types of growth factors of current clinical interest, including those used to accelerate bone repair, treat ischemic tissue and wound healing. Initial animal studies have shown that one of the analogs speeds healing of deep skin wounds. Other animal studies suggest that the analogs may also be useful in treating mucositis, a side effect of some cancer treatments. Therefore, this technology could serve several large and different market needs."
The National Institutes of Health and BioSET supported this research.

About BioSurface Technologies, Inc.
BioSurface Engineering Technologies, Inc., a private, development-stage company, has over 12 years of development expertise in organic and plasma chemistries designed to enhance surface characteristics of medical products. The company is focused on licensing its proprietary lubricious, thrombo-resistant and diffusion barrier technologies to medical device manufacturers around the world. In addition, BioSET maintains an active program in synthetic peptide development as an alternative to recombinant production methodologies and loco-regional delivery technology for biomedical and biopharmaceutical industries. BioSET's web address is

About Brookhaven National Laboratory
The U.S. Department of Energy's Brookhaven National Laboratory ( conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies. Brookhaven also builds and operates major facilities available to university, industrial, and government scientists. The Laboratory is managed by Brookhaven Science Associates, a limited liability company founded by Stony Brook University and Battelle, a nonprofit applied science and technology organization. Visit Brookhaven Lab's electronic newsroom for links, news archives, graphics, and more:

DOE/Brookhaven National Laboratory

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to